By Chris Wack
Shares of Telomir Pharmaceuticals climbed up 20% to $5.10 after the company said it saw positive pre-clinical results confirming the efficacy of its licensed molecule Telomir-1 in reversing several key parameters of Type 2 diabetes mellitus.
The pre-clinical stage pharmaceutical company said the study demonstrated significant reductions in fasting plasma glucose levels to basal levels, improvements in oral glucose homeostasis, and the reversal of insulin resistance to near pre-diabetic levels.
The Miami company said that these effects were also accompanied by increased survival rates in treated subjects, highlighting Telomir-1's ability to potentially address the underlying mechanisms of Type 2 diabetes.
Telomir had its initial public offering in February, with 1 million shares pricing at $7 a share.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 03, 2024 12:04 ET (17:04 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.